Bonus Biogroup (BONS) - Cash Flow Conversion Efficiency

Latest as of June 2025: 2.402x

Based on the latest financial reports, Bonus Biogroup (BONS) has a cash flow conversion efficiency ratio of 2.402x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA-4.02 Million ≈ $-10.79K USD) by net assets (ILA-1.68 Million ≈ $-4.49K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Bonus Biogroup net asset quality index to measure how much of total assets are equity-financed.

Bonus Biogroup - Cash Flow Conversion Efficiency Trend (2008–2025)

This chart illustrates how Bonus Biogroup's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check BONS cash flow quality score to evaluate the quality of earnings relative to operating cash generation.

Bonus Biogroup Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Bonus Biogroup ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Cartica Acquisition Corp
NASDAQ:CITE
-0.025x
Maywufa Co Ltd
TW:1731
0.033x
Applied BioCode
TW:6598
-0.029x
IBI Lion SOCIMI S.A.
MC:YIBI
0.006x
Terracom Ltd
AU:TER
-0.082x
Torque Metals Ltd
AU:TOR
-0.008x
Haivision Systems Inc
TO:HAI
0.127x
G Collado S.A.B. de C.V
MX:COLLADO
0.494x

Annual Cash Flow Conversion Efficiency for Bonus Biogroup (2008–2025)

The table below shows the annual cash flow conversion efficiency of Bonus Biogroup from 2008 to 2025. For the full company profile with market capitalisation and key ratios, see BONS company net worth.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 ILA-5.66 Million
≈ $-15.18K
ILA-14.93 Million
≈ $-40.03K
2.636x +185.81%
2024-12-31 ILA6.96 Million
≈ $18.65K
ILA-21.37 Million
≈ $-57.30K
-3.072x -241.08%
2023-12-31 ILA29.30 Million
≈ $78.57K
ILA-26.40 Million
≈ $-70.77K
-0.901x -76.27%
2022-12-31 ILA56.39 Million
≈ $151.18K
ILA-28.82 Million
≈ $-77.25K
-0.511x -8.30%
2021-12-31 ILA84.43 Million
≈ $226.35K
ILA-39.84 Million
≈ $-106.81K
-0.472x +8.05%
2020-12-31 ILA30.68 Million
≈ $82.26K
ILA-15.75 Million
≈ $-42.21K
-0.513x -153.70%
2019-12-31 ILA-13.72 Million
≈ $-36.79K
ILA-13.11 Million
≈ $-35.16K
0.956x -77.39%
2018-12-31 ILA-3.18 Million
≈ $-8.52K
ILA-13.43 Million
≈ $-36.00K
4.226x +128.21%
2017-12-31 ILA-6.38 Million
≈ $-17.12K
ILA-11.82 Million
≈ $-31.70K
1.852x +41.67%
2016-12-31 ILA-7.36 Million
≈ $-19.74K
ILA-9.62 Million
≈ $-25.80K
1.307x -77.50%
2015-12-31 ILA-1.39 Million
≈ $-3.72K
ILA-8.07 Million
≈ $-21.63K
5.809x +144.38%
2014-12-31 ILA604.00K
≈ $1.62K
ILA-7.91 Million
≈ $-21.20K
-13.091x -1005.65%
2013-12-31 ILA6.45 Million
≈ $17.28K
ILA-7.63 Million
≈ $-20.46K
-1.184x +8.53%
2012-12-31 ILA7.47 Million
≈ $20.03K
ILA-9.67 Million
≈ $-25.93K
-1.294x -132.19%
2011-12-31 ILA-881.00K
≈ $-2.36K
ILA-3.54 Million
≈ $-9.50K
4.022x +7812.81%
2010-12-31 ILA-38.19 Million
≈ $-102.39K
ILA-1.94 Million
≈ $-5.20K
0.051x -63.07%
2009-12-31 ILA-9.38 Million
≈ $-25.15K
ILA-1.29 Million
≈ $-3.46K
0.138x -92.04%
2008-12-31 ILA11.86 Million
≈ $31.81K
ILA20.52 Million
≈ $55.01K
1.730x --

About Bonus Biogroup

TA:BONS Israel Biotechnology
Market Cap
$86.42 Million
ILA32.23 Billion ILA
Market Cap Rank
#19678 Global
#256 in Israel
Share Price
ILA27.60
Change (1 day)
-1.08%
52-Week Range
ILA21.10 - ILA58.50
All Time High
ILA171.00
About

Bonus BioGroup Ltd., a clinical-stage biotechnology company, develops products based on tissue engineering and cell therapy. The company's products under development include BonoFill for the treatment of bone tissue regeneration in maxillofacial and orthopedic indications, and defects in limb and jaw bones which is in Phase II clinical trial, as well as in a preclinical stage for the treatment of… Read more